• A new tool for modeling the human gut mi

    From ScienceDaily@1337:3/111 to All on Thu Aug 6 21:30:30 2020
    A new tool for modeling the human gut microbiome

    Date:
    August 6, 2020
    Source:
    Massachusetts Institute of Technology
    Summary:
    Engineers have designed a device that replicates the lining of
    the colon.

    With the device, they can grow human colon cells along with oxygen-
    intolerant bacteria that normally live in the human digestive
    tract and have been implicated in Crohn's disease.



    FULL STORY ========================================================================== Several thousand strains of bacteria live in the human gut. Some of
    these are associated with disease, while others have beneficial effects
    on human health.

    Figuring out the precise role of each of these bacteria can be difficult, because many of them can't be grown in lab studies using human tissue.


    ==========================================================================
    This difficulty is especially pronounced for species that cannot live
    in oxygen-rich environments. However, MIT biological and mechanical
    engineers have now designed a specialized device in which they can grow
    those oxygen- intolerant bacteria in tissue that replicates the lining
    of the colon, allowing them to survive for up to four days.

    "We thought it was really important to contribute a tool to the community
    that could be used for this extreme case," says Linda Griffith, the School
    of Engineering Professor of Teaching Innovation in MIT's Department
    of Biological Engineering. "We showed that you can grow these very
    fastidious organisms, and we were able to study the effects they have on
    the human colon." Using this system, the researchers showed that they
    could grow a strain of bacteria called Faecalibacterium prausnitzii,
    which lives in the human gut and protects against inflammation. They
    also showed that these bacteria, which are often diminished in patients
    with Crohn's disease, appear to exert many of their protective effects
    through the release of a fatty acid called butyrate.

    Griffith and David Trumper, an MIT professor of mechanical engineering,
    are the senior authors of the study, which appears today in the journal
    Med. MIT postdocs Jianbo Zhang and Yu-Ja Huang are the lead authors of
    the paper.

    Oxygen sensitivity The human gut's complex microbiome environment is
    difficult to model using animals such as mice, in part because mice eat
    a very different diet from humans, Griffith says.



    ========================================================================== "We've learned a huge amount from mice and other animal models, but there
    are a lot of differences, especially when it comes to the gut microbiome,"
    she says.

    Most of the bacteria that live in the human gut are anaerobic, meaning
    that they do not require oxygen to survive. Some of these bacteria can
    tolerate low levels of oxygen, while others, such as F. prausnitzii,
    cannot survive oxygen exposure, which makes it difficult to study them
    in a laboratory. Some researchers have designed devices in which they
    can grow human colon cells along with bacteria that tolerate low levels
    of oxygen, but these don't work well for F. prausnitzii and other highly oxygen-intolerant microbes.

    To overcome this, the MIT team designed a device that allows them to
    precisely control oxygen levels in each part of the system. Their device contains a channel that is coated with cells from the human mucosal
    barrier of the colon.

    Below these cells, nutrients are pumped in to keep the cells alive. This
    bottom layer is oxygen-rich, but the concentration of oxygen decreases
    toward the top of the mucosal cell layer, similarly to what happens in
    the interior of the human colon.

    Just as they do in the human colon, the barrier cells in the channel
    secrete a dense layer of mucus. The MIT team showed that F. prausnitzii
    can form clouds of cells in the outer layer of this mucus and survive
    there for up to four days, in an environment that is kept oxygen-free
    by fluid flowing across it.

    This fluid also contains nutrients for the microbes.

    Using this system, the researchers were able to show that F. prausnitzii
    does influence cell pathways involved in inflammation. They observed
    that the bacteria produce a short-chain fatty acid called butyrate,
    which has previously been shown to reduce inflammation. After butyrate
    levels went up, the mucosal cells showed a reduction in the activity of
    a pathway called NF kappa B. This reduction calms inflammation.



    ========================================================================== "Overall, this pathway has been reduced, which is really similar to what
    people have seen in humans," Zhang says. "It seems that the bacteria
    are desensitizing the mammalian cells to not overreact to the dangers
    in the outside environment, so the inflammation status is being calmed
    down by the bacteria." Patients with Crohn's disease often have reduced
    levels of F. prausnitzii, and the lack of those bacteria is hypothesized
    to contribute to the overactive inflammation seen in those patients.

    When the researchers added butyrate to the system, without bacteria,
    it did not generate all of the effects that they saw when the bacteria
    were present. This suggests that some of the bacteria's effects may be
    exerted through other mechanisms, which the researchers hope to further investigate.

    Microbes and disease The researchers also plan to use their system to
    study what happens when they add other species of bacteria that are
    believed to play a role in Crohn's disease, to try to further explore
    the effects of each species.

    They are also planning a study, working with Alessio Fasano, the division
    chief of pediatric gastroenterology and nutrition at Massachusetts General Hospital, to grow mucosal tissue from patients with celiac disease and
    other gastrointestinal disorders. This tissue could then be used to study microbe- induced inflammation in cells with different genetic backgrounds.

    "We are hoping to get new data that will show how the microbes and
    the inflammation work with the genetic background of the host, to see
    if there could be people who have a genetic susceptibility to having
    microbes interfere with the mucosal barrier a little more than other
    people," Griffith says.

    She also hopes to use the device to study other types of mucosal barriers, including those of the female reproductive tract, such as the cervix
    and the endometrium.

    The research was funded by the U.S. National Institutes of Health,
    the Boehringer Ingelheim SHINE Program, and the National Institute of Environmental Health Sciences.


    ========================================================================== Story Source: Materials provided by
    Massachusetts_Institute_of_Technology. Original written by Anne
    Trafton. Note: Content may be edited for style and length.


    ========================================================================== Journal Reference:
    1. Jianbo Zhang, Yu-Ja Huang, Jun Young Yoon, John Kemmitt, Charles
    Wright,
    Kirsten Schneider, Pierre Sphabmixay, Victor Hernandez-Gordillo,
    Steven J. Holcomb, Brij Bhushan, Gar Rohatgi, Kyle Benton, David
    Carpenter, Jemila C. Kester, George Eng, David T. Breault,
    Omer Yilmaz, Mao Taketani, Christopher A. Voigt, Rebecca
    L. Carrier, David L. Trumper, Linda G. Griffith. Primary Human
    Colonic Mucosal Barrier Crosstalk with Super Oxygen-Sensitive
    Faecalibacterium prausnitzii in Continuous Culture. Med, 2020;
    DOI: 10.1016/j.medj.2020.07.001 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2020/08/200806153555.htm

    --- up 3 weeks, 1 day, 1 hour, 55 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)